Lantheus Medical Imaging [NASDAQGM: LNTH]: Advancing the Art of Medical Imaging
Mary Anne Heino, President & CEO
Offering doctors access to images with the greatest possible degree of definition, contrast and detailed information enhances the depth of diagnosis magnifying results. Lantheus Medical Imaging [NASDAQGM: LNTH] is proudly committed to advancing the art and science of medical imaging. With 60 years of experience in the field of diagnostic imaging Lantheus assists physicians enhance patient care with their rich heritage and expertise in cardiovascular imaging and nuclear medicine.
Lantheus recognizes the potential improvements in image quality and ability to quantify tissue perfusion and additional physiological information impacting medical treatment and outcomes in the overall population and particularly in those still underserved. They have since established a portfolio of three internally-discovered imaging agents in clinical and preclinical development, each of which has the potential to significantly enhance current imaging modalities and execute unmet diagnostic medical imaging needs. Presently, their Positron Emission Tomography (PET), Myocardial Perfusion Imaging (MPI) agent, and Flurpiridaz F 18, are in Phase 3 clinical studies.
The company’s commitment towards healthcare and innovation has been solidified with the approval and launch of one of their most successful radiopharmaceutical— Cardiolite. A myocardial perfusion agent, Cardolite is used at indicating and detecting coronary artery disease by localizing myocardial ischemia-reversible defects and infarction-non-reversible defects, in evaluating myocardial function and developing information for use in patient management decisions. Lantheus uses Cardiolite evaluation of myocardial ischemia to accomplish cardiovascular stress techniques, for example: pharmacologic stress in accordance with the pharmacologic stress agent’s labeling. Cardiolite became the first technetium-labeled myocardial perfusion imaging tracer to provide physicians with prognostic information helpful in making patient management decisions related to coronary artery disease.
We will continue to provide industry-leading nuclear medicine products and contrast agents to healthcare providers and their patients for the years to come
Another pioneering product of the company is DEFINITY— an echocardiography contrast agent in the U.S., that has further advanced Lantheus’ reputation as a pioneer in offering products that are significant in evaluating cardiac health. DEFINITY is an injectable cardiovascular ultrasound contrast agent comprised of lipid-coated echogenic microbubbles filled with octafluoropropane gas enhancing clinicians’ view of the left ventricle of the heart during an echocardiogram to support diagnosis. As a fully synthetic ultrasound contrast agent, DEFINITY has an established safety profile and has been used in more than 7 million echocardiography patients in multiple clinical settings. DEFINITY offers a proven diagnostic advantage that optimizes patient management, outcomes and cost-effectiveness through: small and consistently-sized durable microbubbles, extensive safety experience, and several administration options to meet patient- and practice-specific needs.
Advancing the art and science of imaging, Lantheus is developing next generation imaging agents to enhance the accuracy, reliability and safety of diagnostic imaging. The company believes their pipeline products have the potential to significantly enhance current imaging modalities and fulfill unmet diagnostic medical imaging needs. Lantheus' pipeline agents include Flurpiridaz F 18—a MPI agent, Cardiac Neuronal Agent (CNA)—that allows better identification of patients at risk of Sudden Cardiac Death (SCD) alongside Vascular Remodeling Imaging—used to risk stratify patients for potential vascular events, including heart attack or stroke.
Lantheus continues to enhance current imaging modalities and fulfill unmet diagnostic medical imaging needs. In addition to their diversified portfolio of commercialized imaging agents and products, the company has a strong development pipeline of internally-discovered next generation, first-in-class imaging agents that use PET and MRI technologies focused on developing the present imaging modalities. “We will continue to provide industry-leading nuclear medicine products and contrast agents to healthcare providers and their patients for the years to come,” says Mary Anne Heino, President and CEO of Lantheus.
This content is copyright protected
However, if you would like to share the information in this article, you may use the link below: